TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Necchi, A; Guerrero-Ramos, F; Crispen, PL; Herrera-Imbroda, B; Garje, R; Powles, T; Peyton, CC; Pradere, B; Ku, JH; Shore, N; Bögemann, M; Preston, MA; Xylinas, E; Llano, CSD; Hasan, M; Stitou, H; Bhanvadia, S; Sweiti, H; Psutka, S – 2025 –...

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532) – EUROPEAN UROLOGY ONCOLOGY

Tombal, BF; Gomez-Veiga, F; Gomez-Ferrer, A; López-Campos, F; Ost, P; Roumeguere, TA; Herrera-Imbroda, B; D’Hondt, LA; Quivrin, M; Gontero, P; Villà, S; Khaled, H; Fournier, B; Musoro, J; Krzystyniak, J; Pretzenbacher, Y; Loriot, Y – 2024 –...